What Happened?
Rockville, MD-based Autolus Retired Andrew Oakley as Chief Financial Officer
About the Company
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
About the Person
Andrew Oakley is Chief Financial Officer at Autolus. Previously, Andrew held various senior HR leadership roles in the industry.
Info Source
News
Short Profile